A Phase I Trial of GW01-200 Tablets in Subjects With Advanced Tumors

Summary

A phase 1, open-label, first-in-human study mainly aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GW01-200 tablets in participants with advanced tumors, including solid tumors and hematological malignancies.

Timeline

Start

2026-06

Primary completion

2029-01

Completion

2029-06

Drugs

Indications